| Variables . | Non-cardiac ward (n = 142 876) . | Cardiac ward (n = 194 279) . | P-value . |
|---|---|---|---|
| Pharmacotherapy | |||
| Low molecular weight heparin (%) | 63 846/120 734 (53%) | 83 223/167 934 (50%) | <0.001 |
| Fondaparinux | 60 060/121 133 (50%) | 75 242/168 577 (45%) | <0.001 |
| Warfarin (%) | 8357/120 040 (7%) | 10 366/166 921 (6%) | <0.001 |
| Unfractionated heparin | 10 643/119 617 (9%) | 32 930/166 376 (20%) | <0.001 |
| Glycoprotein 2b/3a inhibitor (%) | 2579/122 017 (2%) | 7426/169 024 (4%) | <0.001 |
| IV nitrate | 13 010/119 981 (11%) | 24 094/166 887 (14%) | <0.001 |
| Furosemide (%) | 38 875/120 378 (32%) | 44 599/167 376 (27%) | <0.001 |
| Calcium channel blockers (%) | 23 969/120 179 (20%) | 33 689/167 133 (20%) | 0.16 |
| IV beta-blockers (%) | 971/120 689 (0.8%) | 2273/167 860 (1.4%) | <0.001 |
| MRA (%) | 8339/119 730 (7%) | 12 073/165 600 (7%) | 0.001 |
| Thiazide diuretics (%) | 5956/119 771 (5%) | 7730/166 687 (4.6%) | <0.001 |
| Aspirin (%) | 135 989/142 413 (95%) | 188 631/193 737 (97%) | <0.001 |
| P2Y12 inhibitor (%) | 129 478/142 323 (91%) | 179 672/193 534 (93%) | <0.001 |
| Statins (%) | 115 283/141 645 (81%) | 164 792/193 178 (85%) | <0.001 |
| ACE inhibitors/ARB (%) | 110 538/141 607 (78%) | 161 248/193 311 (83%) | <0.001 |
| Beta-blockers (%) | 110 647/140 980 (78%) | 161 757/192 558 (84%) | <0.001 |
| Management strategy | |||
| Radionuclide Study (%) | 3298/123 456 (2.7%) | 3961/164 393 (2.4%) | <0.001 |
| Exercise test | 3030/123 897 (2%) | 7330/168 632 (4%) | <0.001 |
| Coronary angiogram (%) | 80 147/136 934 (59%) | 144 457/184 895 (78%) | <0.001 |
| Percutaneous coronary intervention (%) | 37 361/104 436 (36%) | 82 071/157 704 (52%) | <0.001 |
| CABG (%) | 6821/104 436 (7%) | 12 156/157 704 (8%) | <0.001 |
| Revascularisation (CABG/PCI) | 44 182/104 436 (42%) | 94 227/157 704 (60%) | <0.001 |
| Crude inhospital clinical outcomes | |||
| Death (%) | 8903/142 876 (6.2%) | 5299/194 279 (2.7%) | <0.001 |
| Cardiac mortality (%) | 6829/142 876 (4.8%) | 4373/194 279 (2.2%) | <0.001 |
| Reinfarction (%) | 1229/132 239 (0.9%) | 1572/182 182 (0.9%) | 0.05 |
| Major bleeding (%) | 2340/139 507 (1.7%) | 2396/190 628 (1.3%) | <0.001 |
| MACEa (%) | 9810/142 876 (6.9%) | 6638/194 279 (3.4%) | <0.001 |
| Variables . | Non-cardiac ward (n = 142 876) . | Cardiac ward (n = 194 279) . | P-value . |
|---|---|---|---|
| Pharmacotherapy | |||
| Low molecular weight heparin (%) | 63 846/120 734 (53%) | 83 223/167 934 (50%) | <0.001 |
| Fondaparinux | 60 060/121 133 (50%) | 75 242/168 577 (45%) | <0.001 |
| Warfarin (%) | 8357/120 040 (7%) | 10 366/166 921 (6%) | <0.001 |
| Unfractionated heparin | 10 643/119 617 (9%) | 32 930/166 376 (20%) | <0.001 |
| Glycoprotein 2b/3a inhibitor (%) | 2579/122 017 (2%) | 7426/169 024 (4%) | <0.001 |
| IV nitrate | 13 010/119 981 (11%) | 24 094/166 887 (14%) | <0.001 |
| Furosemide (%) | 38 875/120 378 (32%) | 44 599/167 376 (27%) | <0.001 |
| Calcium channel blockers (%) | 23 969/120 179 (20%) | 33 689/167 133 (20%) | 0.16 |
| IV beta-blockers (%) | 971/120 689 (0.8%) | 2273/167 860 (1.4%) | <0.001 |
| MRA (%) | 8339/119 730 (7%) | 12 073/165 600 (7%) | 0.001 |
| Thiazide diuretics (%) | 5956/119 771 (5%) | 7730/166 687 (4.6%) | <0.001 |
| Aspirin (%) | 135 989/142 413 (95%) | 188 631/193 737 (97%) | <0.001 |
| P2Y12 inhibitor (%) | 129 478/142 323 (91%) | 179 672/193 534 (93%) | <0.001 |
| Statins (%) | 115 283/141 645 (81%) | 164 792/193 178 (85%) | <0.001 |
| ACE inhibitors/ARB (%) | 110 538/141 607 (78%) | 161 248/193 311 (83%) | <0.001 |
| Beta-blockers (%) | 110 647/140 980 (78%) | 161 757/192 558 (84%) | <0.001 |
| Management strategy | |||
| Radionuclide Study (%) | 3298/123 456 (2.7%) | 3961/164 393 (2.4%) | <0.001 |
| Exercise test | 3030/123 897 (2%) | 7330/168 632 (4%) | <0.001 |
| Coronary angiogram (%) | 80 147/136 934 (59%) | 144 457/184 895 (78%) | <0.001 |
| Percutaneous coronary intervention (%) | 37 361/104 436 (36%) | 82 071/157 704 (52%) | <0.001 |
| CABG (%) | 6821/104 436 (7%) | 12 156/157 704 (8%) | <0.001 |
| Revascularisation (CABG/PCI) | 44 182/104 436 (42%) | 94 227/157 704 (60%) | <0.001 |
| Crude inhospital clinical outcomes | |||
| Death (%) | 8903/142 876 (6.2%) | 5299/194 279 (2.7%) | <0.001 |
| Cardiac mortality (%) | 6829/142 876 (4.8%) | 4373/194 279 (2.2%) | <0.001 |
| Reinfarction (%) | 1229/132 239 (0.9%) | 1572/182 182 (0.9%) | 0.05 |
| Major bleeding (%) | 2340/139 507 (1.7%) | 2396/190 628 (1.3%) | <0.001 |
| MACEa (%) | 9810/142 876 (6.9%) | 6638/194 279 (3.4%) | <0.001 |
ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; CABG surgery, coronary artery bypass grafting surgery; IV, intravenous; MACE, major adverse cardiovascular events; MRA, mineralocorticoid receptor antagonist.
aMACE is defined as composite endpoint of inpatient mortality and reinfarction.
| Variables . | Non-cardiac ward (n = 142 876) . | Cardiac ward (n = 194 279) . | P-value . |
|---|---|---|---|
| Pharmacotherapy | |||
| Low molecular weight heparin (%) | 63 846/120 734 (53%) | 83 223/167 934 (50%) | <0.001 |
| Fondaparinux | 60 060/121 133 (50%) | 75 242/168 577 (45%) | <0.001 |
| Warfarin (%) | 8357/120 040 (7%) | 10 366/166 921 (6%) | <0.001 |
| Unfractionated heparin | 10 643/119 617 (9%) | 32 930/166 376 (20%) | <0.001 |
| Glycoprotein 2b/3a inhibitor (%) | 2579/122 017 (2%) | 7426/169 024 (4%) | <0.001 |
| IV nitrate | 13 010/119 981 (11%) | 24 094/166 887 (14%) | <0.001 |
| Furosemide (%) | 38 875/120 378 (32%) | 44 599/167 376 (27%) | <0.001 |
| Calcium channel blockers (%) | 23 969/120 179 (20%) | 33 689/167 133 (20%) | 0.16 |
| IV beta-blockers (%) | 971/120 689 (0.8%) | 2273/167 860 (1.4%) | <0.001 |
| MRA (%) | 8339/119 730 (7%) | 12 073/165 600 (7%) | 0.001 |
| Thiazide diuretics (%) | 5956/119 771 (5%) | 7730/166 687 (4.6%) | <0.001 |
| Aspirin (%) | 135 989/142 413 (95%) | 188 631/193 737 (97%) | <0.001 |
| P2Y12 inhibitor (%) | 129 478/142 323 (91%) | 179 672/193 534 (93%) | <0.001 |
| Statins (%) | 115 283/141 645 (81%) | 164 792/193 178 (85%) | <0.001 |
| ACE inhibitors/ARB (%) | 110 538/141 607 (78%) | 161 248/193 311 (83%) | <0.001 |
| Beta-blockers (%) | 110 647/140 980 (78%) | 161 757/192 558 (84%) | <0.001 |
| Management strategy | |||
| Radionuclide Study (%) | 3298/123 456 (2.7%) | 3961/164 393 (2.4%) | <0.001 |
| Exercise test | 3030/123 897 (2%) | 7330/168 632 (4%) | <0.001 |
| Coronary angiogram (%) | 80 147/136 934 (59%) | 144 457/184 895 (78%) | <0.001 |
| Percutaneous coronary intervention (%) | 37 361/104 436 (36%) | 82 071/157 704 (52%) | <0.001 |
| CABG (%) | 6821/104 436 (7%) | 12 156/157 704 (8%) | <0.001 |
| Revascularisation (CABG/PCI) | 44 182/104 436 (42%) | 94 227/157 704 (60%) | <0.001 |
| Crude inhospital clinical outcomes | |||
| Death (%) | 8903/142 876 (6.2%) | 5299/194 279 (2.7%) | <0.001 |
| Cardiac mortality (%) | 6829/142 876 (4.8%) | 4373/194 279 (2.2%) | <0.001 |
| Reinfarction (%) | 1229/132 239 (0.9%) | 1572/182 182 (0.9%) | 0.05 |
| Major bleeding (%) | 2340/139 507 (1.7%) | 2396/190 628 (1.3%) | <0.001 |
| MACEa (%) | 9810/142 876 (6.9%) | 6638/194 279 (3.4%) | <0.001 |
| Variables . | Non-cardiac ward (n = 142 876) . | Cardiac ward (n = 194 279) . | P-value . |
|---|---|---|---|
| Pharmacotherapy | |||
| Low molecular weight heparin (%) | 63 846/120 734 (53%) | 83 223/167 934 (50%) | <0.001 |
| Fondaparinux | 60 060/121 133 (50%) | 75 242/168 577 (45%) | <0.001 |
| Warfarin (%) | 8357/120 040 (7%) | 10 366/166 921 (6%) | <0.001 |
| Unfractionated heparin | 10 643/119 617 (9%) | 32 930/166 376 (20%) | <0.001 |
| Glycoprotein 2b/3a inhibitor (%) | 2579/122 017 (2%) | 7426/169 024 (4%) | <0.001 |
| IV nitrate | 13 010/119 981 (11%) | 24 094/166 887 (14%) | <0.001 |
| Furosemide (%) | 38 875/120 378 (32%) | 44 599/167 376 (27%) | <0.001 |
| Calcium channel blockers (%) | 23 969/120 179 (20%) | 33 689/167 133 (20%) | 0.16 |
| IV beta-blockers (%) | 971/120 689 (0.8%) | 2273/167 860 (1.4%) | <0.001 |
| MRA (%) | 8339/119 730 (7%) | 12 073/165 600 (7%) | 0.001 |
| Thiazide diuretics (%) | 5956/119 771 (5%) | 7730/166 687 (4.6%) | <0.001 |
| Aspirin (%) | 135 989/142 413 (95%) | 188 631/193 737 (97%) | <0.001 |
| P2Y12 inhibitor (%) | 129 478/142 323 (91%) | 179 672/193 534 (93%) | <0.001 |
| Statins (%) | 115 283/141 645 (81%) | 164 792/193 178 (85%) | <0.001 |
| ACE inhibitors/ARB (%) | 110 538/141 607 (78%) | 161 248/193 311 (83%) | <0.001 |
| Beta-blockers (%) | 110 647/140 980 (78%) | 161 757/192 558 (84%) | <0.001 |
| Management strategy | |||
| Radionuclide Study (%) | 3298/123 456 (2.7%) | 3961/164 393 (2.4%) | <0.001 |
| Exercise test | 3030/123 897 (2%) | 7330/168 632 (4%) | <0.001 |
| Coronary angiogram (%) | 80 147/136 934 (59%) | 144 457/184 895 (78%) | <0.001 |
| Percutaneous coronary intervention (%) | 37 361/104 436 (36%) | 82 071/157 704 (52%) | <0.001 |
| CABG (%) | 6821/104 436 (7%) | 12 156/157 704 (8%) | <0.001 |
| Revascularisation (CABG/PCI) | 44 182/104 436 (42%) | 94 227/157 704 (60%) | <0.001 |
| Crude inhospital clinical outcomes | |||
| Death (%) | 8903/142 876 (6.2%) | 5299/194 279 (2.7%) | <0.001 |
| Cardiac mortality (%) | 6829/142 876 (4.8%) | 4373/194 279 (2.2%) | <0.001 |
| Reinfarction (%) | 1229/132 239 (0.9%) | 1572/182 182 (0.9%) | 0.05 |
| Major bleeding (%) | 2340/139 507 (1.7%) | 2396/190 628 (1.3%) | <0.001 |
| MACEa (%) | 9810/142 876 (6.9%) | 6638/194 279 (3.4%) | <0.001 |
ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; CABG surgery, coronary artery bypass grafting surgery; IV, intravenous; MACE, major adverse cardiovascular events; MRA, mineralocorticoid receptor antagonist.
aMACE is defined as composite endpoint of inpatient mortality and reinfarction.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
